Merck's performance has come under question with its
Q4 earnings beating expectations but its
2026 guidance disappointing investors. This comes amid decent Keytruda sales and positive clinical trial results. There have been movements in Merck's ownership, with several investors and institutions altering their shares including ANTIPODES PARTNERS Ltd, AMG National Trust Bank, ICICI Prudential Asset Management Co Ltd, Vanguard Group Inc, and Skandinaviska Enskilda Banken AB. The
stock's performance has led to a debate, with its value surging 60% and then sliding 2% in the last week. Despite this, Barclays has initiated coverage of Merck with overweight due to upcoming drug launches. Some see Merck's PD-1 ovarian cancer approval and partnership with Mayo AI for drug discovery, providing a boost for investment. Despite presenting a modest guidance due to generic competition, Jim Cramer still considers it one of his favorite pharmaceutical stocks. The future outlook remains unclear as some view the stock as a potential value trap. However, Morgan Stanley raised their Merck price target based on growth outlook while Bernstein also raised their price target citing pipeline optimism. Guggenheim similarly increased theirs due to the Winrevair's potential. Questions remain over the stock's performance and what's fueling its rally. Nevertheless, Wall Street analysts seem optimistic about Merck.
Merck Stocks News Analytics from Tue, 29 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 14:12:59 GMT -
Rating 5
- Innovation 2
- Information 6
- Rumor -3
